Biocept Closes Initial Public Offering, Raises $19M in Gross Proceeds | GenomeWeb

NEW YORK (GenomeWeb News) – Biocept said after the close of the market on Monday that it has closed its initial public offering, raising $19 million in gross proceeds.

The company went public last week with an offering of 1.9 million shares at $10 per share. In afternoon trading on the Nasdaq, Biocept's shares were down a fraction of 1 percent at $8.85.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.